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DOI 10.1016/j.ccr.2010.09.006SUMMARYEpigenetic alterations have been increasingly implicated in oncogenesis. Analysis of Drosophila mutants
suggests that Polycomb and SWI/SNF complexes can serve antagonistic developmental roles. However,
the relevance of this relationship to human disease is unclear. Here, we have investigated functional relation-
ships between these epigenetic regulators in oncogenic transformation. Mechanistically, we show that loss
of the SNF5 tumor suppressor leads to elevated expression of the Polycomb gene EZH2 and that Polycomb
targets are broadly H3K27-trimethylated and repressed in SNF5-deficient fibroblasts and cancers. Further,
we show antagonism between SNF5 and EZH2 in the regulation of stem cell-associated programs and
that Snf5 loss activates those programs. Finally, using conditional mouse models, we show that inactivation
of Ezh2 blocks tumor formation driven by Snf5 loss.INTRODUCTION
Epigenetic modifications, somatically heritable changes in gene
expression derived fromchanges in chromatin structure not from
changes in DNA sequence, serve crucial roles in cell fate deci-
sions and are increasingly appreciated as having roles in onco-
genic transformation (Jones and Baylin, 2007; McKenna and
Roberts, 2009; Sparmann and van Lohuizen, 2006). Global alter-
ations in covalent histone-tail modifications, such as acetylation,
methylation, and phosphorylation, are frequently observed in
cancer, as are aberrant expression of enzymes mediating these
reactions (Wang et al., 2007a). Alterations in nucleosome posi-
tioning are also contributors to oncogenesis, and specific muta-
tions in chromatin remodeling complexes that utilize ATP to
reposition nucleosomes contribute to the formation of a growingSignificance
While epigenetic alterations are widely present in cancers, in th
mine the degree to which epigenetic alterations serve as prima
the SNF5 chromatin remodeling subunit, despite being highly
making them an ideal model for this purpose. Here, we dem
SNF5 loss arises due to imbalanced epigenetic antagonism b
PRC2. Collectively, our work reveals essential roles for epigene
that inactivation of EZH2 can have therapeutic efficacy agains
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instability is present in most cancers, a subset of aggressive
cancers are diploid and largely devoid of genomic alterations
suggesting that genomic instability is dispensable for cancer
formation and further highlighting important contributions of
epigenetic alterations in oncogenesis (McKenna et al., 2008;
McKenna and Roberts 2009). Gaining insight into the mecha-
nisms by which epigenetic alterations drive cancer formation is
an area of intense interest in cancer research because unlike
DNA mutations epigenetic modifications are reversible, raising
the possibility that therapeutics that specifically target epige-
netic modifiers may be more effective in the treatment of cancer.
While epigenetically based changes are increasingly recognized,
the underlying mechanisms and contributions of individual chro-
matin modifying enzymes are not well understood.e context of genomic instability it has been difficult to deter-
ry drivers of tumorigenesis. Cancers initiated by mutation of
aggressive and lethal, are diploid and genomically stable,
onstrate that the rapid onset of tumor formation following
etween the SWI/SNF complex and the Polycomb complex
tic modifications during tumor formation and demonstrates
t cancer in vivo.
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Antagonism between Polycomb and SWI/SNFProteins from the Polycomb group (PcG) contribute to epige-
netically based gene silencing during development and evidence
is emerging to suggest that they may serve important roles
during oncogenic transformation (Bracken and Helin, 2009;
Simon and Lange, 2008). The PcG protein EZH2 is highly
expressed in a range of cancer types, including breast, prostate,
and lymphomas, and is often correlated with advanced stages of
tumor progression and poor prognosis, although the mecha-
nisms underlying the upregulation of EZH2 are poorly under-
stood. EZH2 serves as the catalytic subunit in the PRC2 poly-
comb repressor complex and mediates gene silencing by
catalyzing the trimethylation of histone 3 lysine 27 (H3K27) at
the promoters of target genes. A number of studies, using tumor
cell lines, have concluded that EZH2 may contribute to onco-
genic transformation. Similarly, reducing the levels of EZH2
leads to growth inhibition and reduced tumor formation in tumor
cell line transplantation models (Varambally et al., 2002; Bracken
et al., 2003; Simon and Lange 2008). Collectively, these findings
have led to the hypothesis that overexpression of EZH2 is an
important driver of oncogenesis and that targeted inactivation
of EZH2 may have therapeutic efficacy against these cancers
in vivo.
Accumulating evidence has suggested that SWI/SNF
complexes oppose epigenetic silencing by PcG proteins. Antag-
onistic relationships between SWI/SNF components and PcG
proteins were first uncovered via genetic studies in Drosophila
where mutations in core components of the SWI/SNF complex
were found to suppress defects in body segment identity
conferred by mutations in PcG proteins (Kennison and Tamkun,
1988). Insight into the underlying mechanism came when it was
discovered that PcG proteins maintain repression of Hox genes
during embryogenesis, while the SWI/SNF complex promotes
Hox gene activation (Kennison, 1995; Tamkun et al., 1992).
Subsequent in vitro work with mammalian proteins showed
that SWI/SNF complexes mediate changes in gene expression
by utilizing the energy of ATP to reposition nucleosomes and
remodel chromatin and that this enzymatic activity can be coun-
teracted by PcG proteins (Shao et al., 1999; Francis et al., 2001).
Last, re-expression of SNF5 into a SNF5-deficient tumor cell line
led to increased activation of the tumor suppressor protein
p16INK4a and removal of PcG proteins at the p16INK4a locus
(Kia et al., 2008; Oruetxebarria et al., 2004). Intriguingly, while
PcG proteins are frequently overexpressed in cancer, core
components of the SWI/SNF complex are frequently inactivated
in cancer.
The SWI/SNF complex represents a novel link between epige-
netic regulation and tumor suppression. Inactivation of the core
SNF5 subunit leads to aggressive cancer formation and a familial
cancer predisposition syndrome. Malignant rhabdoid tumors,
which arise in the brain, kidney, and other soft tissues following
biallelic inactivation of SNF5, are aggressive and highly lethal
cancers that strike young children. The list of tumors with
frequent loss of SNF5 is expanding and includes several aggres-
sive cancers (Reisman et al., 2009; Roberts and Biegel, 2009).
Mouse models have validated the tumor suppressor function
of Snf5 as heterozygous Snf5mice are tumor prone and biallelic
conditional inactivation of Snf5 leads to fully penetrant cancer
formation with a median onset of 11 weeks (Guidi et al., 2001;
Klochendler-Yeivin et al., 2000; Roberts et al., 2000, 2002).CFurthermore, accumulating evidence raises the possibility that
SWI/SNF complexes have a more widespread role in preventing
tumorigenesis as specific mutations of this complex have been
identified in cancers of the lung, breast, prostate, and pancreas
(Roberts and Orkin, 2004; Medina et al., 2008; Reisman et al.,
2009). While perturbations in SWI/SNF complexes can lead to
aggressive widespread tumor formation, the mechanism under-
lying the formation of these tumors has remained elusive.
Accumulating evidence suggests that epigenetic changes play
a critical role in the genesis of cancer. The presence of genome
instability and widespread genetic mutations in the majority of
cancers makes it difficult to evaluate the role of epigenetic alter-
ations as it is unclear which, if any, of these epigenetic alterations
are primary drivers of cancer and which are secondary passen-
gers. In contrast, SNF5-deficient cancers, despite being highly
aggressive, are diploid and genomically stable, suggesting a crit-
ical epigenetic influence and making them an ideal model with
which to elucidate epigenetic drivers of oncogenesis (McKenna
et al., 2008; McKenna and Roberts 2009).
Here, we investigate a functional relationship between SNF5
and EZH2 in oncogenic transformation by examining the role
of EZH2 in driving SNF5-deficient tumors.
RESULTS
Ezh2 Is Upregulated in Snf5-Deficient Tumors
To investigate whether activation of PcG function contributes to
the oncogenic drive caused by SNF5 loss, we evaluated PcG
gene expression in SNF5-deficient tumors. We first examined
PcG gene expression signatures from primary CNS rhabdoid
tumors and cell lines compared with expression signatures
from normal cerebellum. MRTs expressed higher levels of
EZH2 (Figure 1A; p < 0.0001), whereas other PcG transcripts
were upregulated in some samples but were not consistently
affected (Figures S1A–S1D; EED, p = 0.54; SUZ12, p = 0.03;
BMI1, p = 0.97). In order to evaluate the relative magnitude of
this effect, we compared the levels of PcG transcripts in SNF5-
deficient samples with prostate cancers because these tumors
have been shown to express EZH2 at high levels in metastatic
cancers or low levels in primary tumors (Varambally et al.,
2002). We utilized previously published microarray data sets
downloaded from the Gene Expression Omnibus database
repository (GEO) (Edgar et al., 2002) and found that EZH2 was
most highly expressed in MRTs exceeding even the levels in
metastatic prostate cells (Figure 1B, p = 0.01; Actin control,
Figure S1E). Taken together, these results reveal elevated levels
of EZH2 in SNF5-deficient tumors.
We next sought to determine whether PcG genes were also
upregulated in primary tumors that arise following conditional
inactivation of Snf5 in the mouse T cell lineage. In this mouse
model of cancer, inactivation of Snf5 in peripheral T cells rapidly
gives rise to fully penetrant CD8+ T cell lymphomas, thus
providing a tumor model with which we could investigate func-
tional relationships between PcG proteins and the SWI/SNF
complex during oncogenic transformation (Isakoff et al., 2005;
Roberts et al., 2002; Wang et al., 2009b). Comparison of gene
expression signatures from purified CD8+ Snf5-deficient
lymphoma T cells to wild-type control CD8+ T cells revealed
markedly increased levels of the Ezh2 transcript in all lymphomaancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc. 317
Figure 1. EZH2 Is Elevated in SNF5-Defi-
cient Cancers and Following Snf5 Inactiva-
tion in Primary Cells
(A and B) Scatter plot of EZH2 expression in (A)
primary MRT compared with normal cerebellum
and (B) in MRT compared with prostate tumors.
(C) Heat map showing expression of PcG tran-
scripts in murine Snf5-deficient CD8+ T cell
lymphoma cells compared with purified wild-type
CD8+ T cells. Relative expression values are
normalized across each row where red indicates
high-level expression and blue indicates low-level
expression.
(D) Ezh2 protein levels are elevated in Snf5-defi-
cient lymphomas. Immunoblot analysis of Ezh2
in CD8+ T cells compared with Snf5-deficient
CD8+ lymphoma T cells.
(E) Ezh2 mRNA levels are upregulated following
Snf5 inactivation in MEFs. Heat map showing
expression of PcG genes following Cre-mediated
excision of Snf5 in MEFs compared with control
MEFs.
(F) Ezh2 protein levels are upregulated following
Snf5 inactivation in MEFs. Immunoblot analysis
of Ezh2 and Snf5 from whole-cell extracts derived
from control MEFs or Snf5-deficient MEFs. Actin is
used as a loading control.
See also Figure S1.
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Antagonism between Polycomb and SWI/SNFsamples (Figure 1C; Figure S1F; p = 0.0002). These analyses also
showed a trend toward upregulation of other PcG proteins
although this was not as consistent (Figure 1C; Figure S1G–
S1J; Eed, p = 0.19; Suz12, p = 0.08; Bmi1, p = 0.09). Ezh2 upre-
gulation was confirmed using immunoblotting, which revealed
a robust increase of Ezh2 protein in Snf5-deficient lymphomas
(Figure 1D).Snf5 Directly Represses Ezh2 Transcription in Mouse
Embryonic Fibroblasts
To determine whether the elevated levels of Ezh2 detected in
Snf5-deficient tumors was a primary effect of Snf5 inactivation,
we next evaluated PcG expression in mouse embryonic fibro-
blasts (MEFs) conditional for Snf5. We first utilized whole-
genome expression data sets that we generated from Snf5-defi-
cient MEFs compared with control MEFs to evaluate changes in
PcG gene expression caused by Snf5 loss (Isakoff et al., 2005).
The PcG gene Ezh2was reproducibly upregulated in all samples
following Snf5 depletion (p = 0.004), whereas the expression of
other PcG transcripts, Eed (p = 0.50), Suz12 (p = 0.76), and
Bmi1 (p = 0.15), did not show consistent patterns of upregulation
(Figure 1E; Figure S1K–S1O). Ezh2 protein levels also increased
following Snf5 inactivation (Figure 1F). To gain insight into318 Cancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc.whether the SWI/SNF complex directly
regulates EZH2 expression, we tested
for binding of Snf5 at the genomic locus
of Ezh2 in MEFs. Using chromatin immu-
noprecipitation (ChIP), we examined Snf5
and RNA Polymerase II occupancy at
Ezh2 compared with three negative
control locations and observed enrich-ment of Snf5 at the Ezh2 gene, but not at control genes (Figures
S1P and S1Q).
Ezh2 Drives Epigenetic Silencing of p16INK4a Following
SNF5 Loss
Downregulation of the p16INK4a tumor suppressor occurs
following inactivation of SNF5 and may contribute to oncogen-
esis (Isakoff et al., 2005; Oruetxebarria et al., 2004). p16INK4a
has also been shown to be a target of EZH2 and to be repressed
by PcG-mediated silencing (Kia et al., 2008; Kotake et al., 2007;
Shen et al., 2008). Further, re-expression of SNF5 in humanMRT
cell lines leads to accumulation of SWI/SNF at the p16INK4a
promoter and is associated with loss of PcG proteins
(Kia et al., 2008). Therefore, we sought to utilize p16INK4a as
a model target to investigate the functional relationship between
EZH2 and SNF5 in primary cells. We crossed Snf5-conditional
mice to Ezh2-conditional mice and isolated MEFs of three geno-
types: Snf5-conditional, Ezh2-conditional, and Snf5-Ezh2
doubly conditional. We evaluated p16INK4a expression after inac-
tivation of Ezh2 or Snf5 or both. Consistent with previous reports,
Snf5 inactivation alone resulted in silencing of p16INK4a (Isakoff
et al., 2005). In contrast, inactivation of Ezh2 led to upregulation
of p16INK4a (Figure 2A). Finally, inactivation of Ezh2 abrogated
the downregulation effect of Snf5 loss upon p16INK4a expression
Figure 2. EZH2 and SNF5 Have Antagonistic Roles in the Control
of Expression of the Model Target p16INK4a
(A) Immunoblot analysis of p16INK4a and p19ARF after inactivation of Snf5 and
Ezh2 in MEFs. Actin was used as a loading control.
(B) ChIP analysis of H3K27me3 levels at the INK4a/ARF locus after Snf5 inac-
tivation in MEFs. Primers were designed at the p19ARF and p16INK4a loci
(primers A, B, and C), as indicated in the schematic illustration in the bottom
panel, and at several negative control regions (Actin promoter [Actin P.] and
Actin intron [Actin In.]). Data are represented as mean ± SEM from three
biological replicates.
(C) Immunoblot analysis of p16INK4a and p14ARF after EZH2 knockdown in
the G401 MRT cell line. Actin was used as a loading control.
See also Figure S2.
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MEFs (Figure 2A). To test whether this antagonism was revers-
ible, 3 days after inactivation of Snf5 and Ezh2, we reintroduced
Snf5 and found that p16INK4a expression was restored to a highClevel, demonstrating reversibility (Figure S2). Since Ezh2 is
thought to mediate epigenetic gene silencing through the addi-
tion of tri-methyl groups to lysine 27 of histone H3, we evaluated
whether this histone modification was elevated at the p16INK4a
locus after Snf5 inactivation. Using chromatin immunoprecipita-
tion (ChIP), we quantified the relative levels of H3K27 trimethyla-
tion at the p16INK4a locus after Snf5 inactivation in MEFs. Snf5
inactivation led to elevated levels of H3K27 trimethylation at
the p16INK4a gene, consistent with a role for Ezh2 in driving
epigenetic gene silencing after Snf5 inactivation (Figure 2B).
To evaluate the relevance to human cancers, we next investi-
gatedwhether EZH2was essential for maintaining the epigenetic
silencing of p16INK4a in a human SNF5-deficient MRT cell line.
Using a shRNA against EZH2, we were able to achieve greater
than 90% knockdown of EZH2, as determined at the protein
level. Expression of the EZH2 shRNA, but not the nonsilencing
shRNA, led to increased expression of p16INK4a (Figure 2C),
showing that EZH2 is required for epigenetic silencing of
p16INK4a.
Repression of Polycomb Signatures in Snf5-Deficient
Tumors and Following Snf5 Inactivation in MEFs
The findings at the p16INK4a locus were supportive of epigenetic
antagonism between SNF5 and EZH2. However, downregula-
tion of p16INK4a is unlikely to be the full mechanism by which
SNF5 loss drives cancer formation as tumor onset occurs
much more quickly, with higher penetrance, and in a different
spectrum following Snf5 inactivation than p16INK4a inactivation
(Krimpenfort et al., 2001; Sharpless et al., 2001). Also, humans
with biallelic p16INK4a mutations are not predisposed to develop
MRT (Kim and Sharpless, 2006; Roberts and Biegel, 2009). Last,
both SWI/SNF and PcGbind the genome atmany loci rather than
just at p16INK4a. Consequently, we sought to determine whether
the epigenetic antagonism between SNF5 and EZH2 was more
broad. We began with an analysis of the expression levels of
PcG targets using Gene Set Enrichment Analysis (GSEA). PcG
targets vary substantially by lineage, and as the cell of origin of
MRTs is unknown but the tumors are poorly differentiated, we
chose to utilize a gene set of PcG targets that had been defined
in embryonic stem cells (Ben-Porath et al., 2008). We found that
these PRC2 targets were downregulated in MRTs compared
with normal brain (Figure 3A; p < 0.001). Consistent with this,
a gene set consisting of H3K27me3 modified targets defined
from embryonic stem cells (Ben-Porath et al., 2008; Lee et al.,
2006) was similarly negatively enriched in rhabdoid tumors
(Figure S3A; p < 0.001). We next used a gene set that we gener-
ated by performing ChIP-chip of H3K27me3 fromprimarymurine
cerebellum to identify H3K27me3 bound targets that were
expressed to some degree to determine whether this gene set
was downregulated in SNF5-deficient rhabdoid tumors. These
genes were even more strongly downregulated in MRTs
(Figure 3B; p < 0.001).
We next turned to our conditional mice to determine whether
the cancers caused by ablation of Snf5 in this model system dis-
played similar alterations in PcG target genes.We thus examined
the expression of a gene set consisting of genes regulated by
Ezh2 within the T cell lineage (Su et al., 2005) and found that
they are also repressed in Snf5-deficient CD8+ T cell lymphomas
compared with normal CD8+ T cells (Figure 3C; p < 0.001).ancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc. 319
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Figure 3. SNF5 Loss Leads to Broad Repression of PcG Targets and Activation of Stem Cell-Associated Programs
GSEA is a method that determines whether a set of genes shows differences between two biological states. The normalized enrichment score (NES) reflects the
degree to which a gene set is upregulated (positive NES) or downregulated (negative NES). Corresponding p values are indicated.
(A and B) (A) GSEA of PRC2 targets from stem cells (Ben-Porath et al., 2008) and (B) H3K27me3 enriched genes from cerebellum in expression data from human
MRT samples compared with normal cerebellum.
(C) GSEA of T cell-specific Ezh2-regulated genes (Su et al., 2005) in expression data from purified CD8+ Snf5-deficient lymphomas compared with CD8+ T cells
purified from a wild-type mouse.
(D and E) (D) GSEA of human fibroblast-specific EZH2-regulated genes (Bracken et al., 2006) and (E) MEF-specific EZH2-regulated genes in expression data from
Snf5-deficient MEFs compared with control MEFs.
(F) GSEA of MEF-specific EZH2-regulated genes in expression data from Snf5 Ezh2-deficient MEFs compared with control MEFs.
(G–L) (G) GSEA of stem cell-associated program in expression data from human MRT samples compared with normal cerebellum, (H) purified CD8+ Snf5-defi-
cient lymphomas compared with CD8+ T cells purified from awild-typemouse, (I) Snf5-deficient MEFs compared with control MEFs, (J) human fibroblasts where
EZH2 levels have been knocked down compared with control fibroblasts, (K) Ezh2-deficient MEFs compared with control MEFs, and (L) Snf5 Ezh2-deficient
MEFs compared with control MEFs. The stem cell-associated expression signatures (Ben-Porath et al., 2008; Wong et al., 2008) and EZH2 knockdown expres-
sion data (Bracken et al., 2006) were previously published.
See also Figure S3. Gene sets are listed in Table S1.
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Antagonism between Polycomb and SWI/SNFA key question is whether repression of PcG-regulated genes
is simply a consequence of oncogenic transformation or whether
it is a primary consequence of Snf5 inactivation. We therefore
utilized Snf5-conditional embryonic fibroblasts to evaluate the
effect of Snf5 inactivation upon PcG-regulated gene expression
in primary nontransformed cells. We found that a gene set
consisting of genes regulated by EZH2 in human fibroblasts
(Bracken et al., 2006) was repressed following Snf5 inactivation
in MEFs (Figure 3D; p < 0.001). We next utilized our Ezh2
conditional MEFs to identify an independently derived set of
Ezh2-regulated genes (Table S1) and found that this gene set
was also downregulated in Snf5-deficient MEFs (Figure 3E;
p < 0.001). To evaluate specificity and to rule out a general
repressive effect caused by Snf5 inactivation, we examined
expression of Ezh2-regulated genes from an unrelated differen-
tiated lineage, T cells, and found them not to be repressed
following Snf5 inactivation in MEFs (Figure S3B) indicating
lineage specificity. Last, we analyzed MEFs derived from
Snf5fl/fl-Ezh2fl/fl double conditional embryos and found that
the absence of Ezh2 indeed blocked the downregulation of
these targets otherwise caused by Snf5 inactivation (Figure 3F).
Taken together, these results show that Snf5 inactivation
leads to broad repression of lineage-specific PcG-regulated
genes and that this repression is dependent upon the presence
of Ezh2.
Snf5 Inactivation Causes Elevated Levels of H3K27me3
at Lineage-Specific PcG Targets
The antagonism between Snf5 and Ezh2 in the control of gene
expression programs prompted us next to investigate the under-
lying mechanism by using ChIP to test whether increased levels
of histone H3K27 trimethylation were present. We thus
performed ChIP-PCR for H3K27me3 from both Snf5-deficient
CD8+ T cell lymphomas and from wild-type CD8+ T cells to
ask whether increased levels of H3K27me3 were present at
genes downregulated by Snf5 loss.We tested 25 downregulated
and 5 nondownregulated control genes. Eighteen of the 25
experimental genes demonstrated statistically significant
increases in H3K27me3 in the Snf5-deficient lymphomas; an
additional 4 of the 25 genes had increased H3K27me3 levels
but were not statistically significant; 2 of the 25 genes were
unchanged and only 1 of the 25 displayed reduced levels of
H3K27me3 in the lymphoma (Figure 4A). In contrast,
H3K27me3 levels were not significantly altered in any of the
five control genes. Consequently, increased levels of
H3K27me3 are present at the promoters of genes downregu-
lated in Snf5-deficient lymphomas.
We next investigated whether increased H3K27 trimethylation
and elevated levels of Ezh2were directly contributing to changes
in gene expression programs following Snf5 inactivation in the
MEF model system. We utilized ChIP-chip to define a set of
508 high-confidence genes bound by H3K27me3 modified
histones in wild-type MEFs and then evaluated how this gene
set was affected by inactivation of Ezh2 and Snf5. Examination
of the list revealed several gene families including Hox, Pax,
and Fox genes that have previously been shown to be regulated
by PcG proteins (Bracken et al., 2006; Table S1). As expected,
given that Ezh2 and the PRC2 complex trimethylate H3K27,
these targets were upregulated in Ezh2-deficient MEFsC(Figure 4B). In contrast, Snf5 inactivation led to further downre-
gulation of the targets (Figure 4C). Coinactivation of Ezh2
blocked the downregulation of these genes otherwise caused
by Snf5 loss, demonstrating an essential role for Ezh2 in this
process (Figure 4D). Of note, the effects of Snf5 inactivation
were specific as genes not bound by H3K27me3 modified
histones in wild-type MEFs were not downregulated
(Figure 4E). We next evaluated the effect of Snf5 inactivation
upon the prevalence of genes modified by H3K27me3 and found
that it led to a 1.9-fold increase (Figure S4).
To gain insight into levels of H3K27me3 at specific genes, we
evaluated its density at promoters. Interestingly, while a 2-fold
elevation of H3K27me3 was present at p16Ink4a, the effect was
even more pronounced at numerous other targets (Figure 4F).
At a few polycomb targets, such as Hoxb1, there appeared to
be minimal change (Figure 4F). To evaluate the effect of Snf5
loss upon Ezh2 targets overall, we examined the set of genes
that are upregulated following Ezh2 inactivation. Inactivation of
Snf5 led to increased signal intensity of both H3K27me3 and
Ezh2 binding overlying the TSS and upstream portion of these
genes (Figure 4G), an effect not seen at control genes such as
actin and Rps8 (Figure 4F) or at a randomly chosen set of
repressed genes not expressed in wild-type MEFs (Figure 4H).
Balanced Expression of StemCell-Associated Programs
by Ezh2 and Snf5
We next sought to investigate the mechanistic basis by which
disruption of the SNF5-PcG balance drives oncogenic transfor-
mation. PcG genes have been implicated in the control of stem
cell identity via the repression of lineage-specific targets (Boyer
et al., 2006; Lee et al., 2006). Similarly, the SWI/SNF complex has
recently been implicated in the control of stem cell self-renewal
and pluripotency (Ho et al., 2009; Kidder et al., 2009). It has
been proposed that oncogenic transformation may depend
upon aberrant ectopic activation of stem cell-related self-
renewal programs (Ben-Porath et al., 2008; Wong et al., 2008).
Therefore, we evaluated the expression gene signatures associ-
ated with identity of embryonic stem cells in Snf5-deficient
tumors. We utilized previously published embryonic stem cell-
associated gene sets and found that these genes are signifi-
cantly upregulated in both humanMRTs (p < 0.001) and inmurine
Snf5-deficient lymphomas (p < 0.001) (Figures 3G and 3H;
Figures S3C and S3D; Wong et al., 2008; Ben-Porath et al.,
2008). As a higher fraction of tumor cells than control cells are
proliferating, we sought to determinewhether proliferation-asso-
ciated genes were driving this enrichment. Therefore, we used
a previously published ‘‘proliferation-corrected’’ gene set from
which the proliferation-associated genes had been removed
(Somervaille et al., 2009). Significant enrichment remained intact
using this gene set as well (MRT, p < 0.001; Snf5-deficient
lymphomas, p < 0.001, Figures S3E and S3F). Again, we sought
to determine whether activation of the stem cell-associated
signature was simply a secondary consequence of oncogenic
transformation or whether it was a primary effect due to Snf5
loss. Therefore, we examined the expression of these gene
sets in Snf5-conditional MEFs and found enrichment of both
the stem cell-associated signatures (p < 0.001) and proliferation
deficient stem cell-associated signatures (p < 0.001) in Snf5-
deficient MEFs (Figure 3I; Figures S3G and S3H). Consequently,ancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc. 321
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Figure 4. Elevated Levels of Ezh2 and H3K27me3 at PcG Target Genes Following Snf5 Loss
(A) ChIP analysis of H3K27me3 in Snf5-deficient lymphomas compared with wild-type CD8+ T cells. The experimental genes represent a random set of genes
downregulated in Snf5-deficient lymphomas whereas the control genes are a random set expressed in both CD8+ T cells and lymphomas. Relative enrichment is
calculated by dividing the H3K27me3 enrichment to input DNA after normalization to a negative binding region in an Actb intron. Data are represented as mean ±
SEM from three biological replicates. *p < 0.05.
(B–D) GSEA enrichment plot of H3K27me3 modified genes in wild-type MEFs in expression data from (B) Ezh2-deficient MEFs, (C) Snf5-deficient MEFs, or (D)
Snf5 Ezh2-deficient MEFs.
(E) GSEA enrichment plot of a random set of non-H3K27me3 genes in expression data from Snf5-deficient MEFs.
(F) H3K27 ChIP-chip at individual gene promoters displayed using the Affymetrix Integrated Genome Browser.
(G and H) (G) H3K27me3 and Ezh2 ChIP-chip signal intensities near the transcription start sites (TSS) of 85 genes most significantly upregulated in Ezh2/MEFs
and (H) 132 randomly chosen control repressed genes not altered in Snf5-deficient or Ezh2-deficient expression data.
See also Figure S4.
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Antagonism between Polycomb and SWI/SNFthe upregulation of stem cell-like programs occurs in primary
cells following Snf5 depletion and is not simply a consequence
of transformation.322 Cancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc.We next evaluated whether the gene expression signatures
associated with stem cells were oppositely regulated by EZH2.
To test this, we examined the expression of these gene
Figure 5. EZH2 Is Required for the Prolifera-
tion of MRT Cell Lines
(A) Slowed proliferation of the G401 MRT cell line
after EZH2 knockdown using shRNAs. Immuno-
blotting was used to determine the efficiency of
EZH2 knockdown. Cell proliferation was deter-
mined using the WST-1 cell proliferation reagent.
Data are represented as mean ± SEM from three
biological replicates.
(B) Slowed proliferation of the G401 MRT cell line
after EZH2 knockdown using siRNAs. Immuno-
blotting was used to determine the efficiency of
EZH2 knockdown. Cells were counted 72 hr after
treatment with the indicated siRNAs. Data are rep-
resented as mean ± SEM from three biological
replicates. *p = 0.01.
(C) The reduced proliferation after shRNA-medi-
ated knockdown of EZH2 is not due to apoptosis.
Apoptosis in EZH2 knockdown or control is
measured via PARP1 cleavage. HeLa cells treated
with doxyrubicin were used as a positive control
for PARP1 cleavage.
(D) EZH2 knockdown leads to cellular senes-
cence. Cellular senescence was determined by
measuring the expression of b-galactosidase.
See also Figure S5.
Cancer Cell
Antagonism between Polycomb and SWI/SNFsignatures in previously published microarray data from human
embryonic fibroblasts in which EZH2 had been knocked down
(Bracken et al., 2006). We found that the stem cell-associated
signatures and a proliferation-deficient stem cell-associated
signature were downregulated following EZH2 knockdown in
primary cells, an effect opposite to that caused by Snf5 loss
(Figure 3J; Figures S3I and S3J). We next utilized our Ezh2-
conditional MEFs and similarly found that these stem cell-
associated signatures were downregulated following Ezh2
inactivation (Figure 3K; Figures S3K and S3L). Finally, we utilized
MEFs from Snf5fl/fl-Ezh2fl/fl double conditional embryos and
found that inactivation of Ezh2 entirely blocked enrichment of
the stem cell-associated signature otherwise caused by Snf5
loss (Figure 3L; Figures S3M and S3N).Ezh2 Is Required for Growth of SNF5-Deficient
Tumor Cells
The antagonism between SNF5 and EZH2 in the control of gene
expression prompted us to ask whether PcG activity is a key
driver of oncogenic transformation following Snf5 loss. We
began by evaluating the effect of EZH2 knockdown in human
SNF5-deficient MRT lines and found that shRNA-mediated
knockdown of EZH2 caused a decrease in cell proliferation (Fig-
ure 5A; Figure S5). To confirm that the slowed proliferation was
not due to off-target effects conferred by expressing the shRNA,
we monitored proliferation after knocking down EZH2 usingCancer Cell 18, 316–328,a different system. We transiently trans-
fected a smartpool of siRNAs that target
EZH2 and then monitored growth by
counting cells after 72 hr. Using this
siRNA-mediated technology, we were
also able to achieve greater than 90%
knockdown of EZH2 and similarlyobserved a reproducible reduction in proliferation compared
with cells that were treated with control siRNAs (Figure 5B).
Thus, EZH2 is required for proliferation of SNF5-deficient cancer
cells.
To gain further insight into how EZH2 is driving tumor forma-
tion, we next evaluated whether the decreased proliferation
following EZH2 knockdown was a result of either apoptosis or
cellular senescence. While EZH2 knockdown revealed no
detectable apoptotic phenotype as measured by cleavage of
PARP1 (Figure 5C), a significant increase in senescence-associ-
ated b-galactosidase expression was detected (Figure 5D).
Further, these cells were larger and flatter, consistent with
senescent morphology. These results suggested that EZH2
contributes to tumorigenesis, at least in part, by preventing the
activation of cellular senescence.Ezh2 Is Essential for Tumor Formation In Vivo
Given our results thus far, we hypothesized that imbalanced
function between EZH2 and SNF5 might serve crucial roles in
driving tumor formation. Therefore, we sought to test in vivo,
using a formal genetic approach, whether inactivating Ezh2
could rescue the tumor phenotype conferred by Snf5 inactiva-
tion in the T cell lineage. Importantly, inactivation of Snf5 in
peripheral T cells confers rapid onset of mature CD8+ T cell
lymphomas in 100% of the mice, thus allowing us to quickly
investigate contributions of Ezh2 to oncogenesis in vivo (RobertsOctober 19, 2010 ª2010 Elsevier Inc. 323
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Figure 6. Ezh2 Is Dispensable for Peripheral T Cell Development
(A) The distribution of peripheral T cells is unaffected by Ezh2 inactivation. Flow cytometry analysis of the CD3 T cell marker on spleen cells isolated frommice of
the indicated genotypes.
(B) Flow cytometry analysis of CD8+ cells, the population from which Snf5-deficient lymphomas ultimately arise, in the spleen from mice of the indicated geno-
type.
(C) An older CD4-Cre Snf5fl/fl mouse in which a lymphoma has developed showing the CD8+ lymphoma population on flow cytometry and gross images of
spleens isolated from a wild-type mouse (control) or lymphoma-bearing mouse.
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Antagonism between Polycomb and SWI/SNFet al., 2002; Wang et al., 2009b). Therefore, we interbred Snf5
and Ezh2 conditional mice in the presence of the CD4-Cre trans-
gene and evaluated whether inactivation of Ezh2 would amelio-
rate the phenotypes caused by Snf5 loss in this lineage. While
inactivation of Snf5 leads to a block in development and a reduc-
tion in peripheral T cell numbers to 30% of wild-type (Figures 6A
and 6B; Roberts et al., 2002), Ezh2 inactivation had no effect
upon the number or distribution of peripheral T cells (Figures
6A and 6B), consistent with previous studies (Su et al., 2005).
We aged cohorts of CD4-Cre expressing Snf5fl/fl, Ezh2fl/fl, and
Snf5fl/fl-Ezh2fl/fl double conditional mice to monitor for tumor324 Cancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc.onset. Strikingly, while Snf5 inactivation led to fully penetrant
and rapid tumor formation (Figure 6C), inactivation of Ezh2
completely blocked tumor onset driven by Snf5 loss (Figure 7).
DISCUSSION
Epigenetics in Tumor Development
Epigenetic alterations likely contribute to the formation ofmost, if
not all cancers. However, in the setting of genomic instability it is
difficult to evaluate the contributions of epigenetic changes as it
is unclear which are primary drivers and which arise as
Figure 7. Ezh2 Is Essential for In Vivo Tumor
Formation after Conditional Snf5 Inactiva-
tion
Tumor-free survival curves of Snf5fl/fl CD4-Cre
(n = 8) and Snf5fl/fl Ezh2 fl/fl CD4-Cre (n = 23) mice.
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Antagonism between Polycomb and SWI/SNFsecondary passengers due to instability (McKenna and Roberts,
2009). We recently showed that SNF5-deficient cancers, both in
humans and mice, are diploid and genomically stable, demon-
strating that disruption of this chromatin remodeling complex
can substitute for chromosomal instability in the genesis of
aggressive, lethal cancers (McKenna et al., 2008). Further, this
suggests that epigenetic alterations play a central role in driving
the formation of these malignancies. Given that they are initiated
by perturbation of a chromatin remodeling complex, their rapid
onset, aggressive nature, and genomic stability, SNF5-deficient
tumors constitute an ideal system with which to evaluate the
epigenetic mechanisms that drive cancer formation.
While previous studies have demonstrated antagonism
between PcG proteins and the SWI/SNF complex in regulating
Hox gene expression inDrosophila, the extent of this relationship
in mammalian development and disease has remained uncertain
(Tamkun et al., 1992; Kennison 1995). Our studies show this
epigenetic relationship is broad based in mammalian cells and
demonstrate that balanced function between SWI/SNF and
PcG serves to prevent tumor formation (Figure 8). As SWI/SNF
is capable of displacing PcG proteins from the INK4a/ARF locus,
our findings are consistent with a model where SWI/SNF and
PcG complexes bind mutually exclusive of one another, a model
supported by nonoverlapping binding profiles on polytene chro-
mosomes and from genome-wide localization studies in
mammalian embryonic stem cells (Armstrong et al., 2002; Kia
et al., 2008; Ho et al., 2009; Kidder et al., 2009). Consequently,
the antagonistic relationship between PcG proteins and the
SWI/SNF complex also serves important roles in preventing
tumor formation in mammals and is a critical component of
tumor formation following Snf5 loss.
EZH2 and Oncogenesis
Accumulating evidence has suggested that EZH2 contributes to
cancer formation. This evidence comes from studies examining
the expression of EZH2 in different tumors, where the highest
levels correlate with the most aggressive tumors and the worst
prognosis (Sparmann and van Lohuizen 2006; Simon and
Lange 2008). Additional studies in a variety of tumor cell lines
have shown that reducing the levels of EZH2 leads to slowed
proliferation and a decreased capacity to form tumors when
transplanted into mice, leading to the proposal of Ezh2 as
a possible therapeutic target (Bracken et al., 2003; Croonquist
and Van Ness, 2005; Kleer et al., 2003; Simon and Lange,Cancer Cell 18, 316–328,2008; Varambally et al., 2002). However,
it has remained unclear whether hyperac-
tivation of EZH2 has roles in the initiation
and maintenance of primary cancers
in vivo and whether targeted inactivation
of EZH2 or its downstream function
would be therapeutically useful. Usingan in vivo cancer model, we show that inactivation of Ezh2 is
sufficient to block tumor formation that occurs after Snf5 loss.
A formal possibility is that Ezh2 could be an essential gene
whose absence prevents cell growth. Several lines of evidence
argue against this and for a specific relationship between PcG
and SWI/SNF. First, as noted above, PcG and SWI/SNF serve
antagonistic roles in control of Hox gene expression (Tamkun
et al., 1992; Kennison 1995). Second, PcG blocks chromatin
remodeling mediated by SWI/SNF in in vitro assays (Francis
et al., 2001; Shao et al., 1999). Third, re-expression of SNF5
leads to PcG eviction from the INK4a/ARF locus (Kia et al.,
2008). Fourth, Ezh2 loss does not have a negative effect upon
T cell number in vivo (Su et al., 2005). Last, we have found that
the effects of Ezh2 inactivation in vivo to be quite specific. For
instance, in a model of osteosarcoma, Ezh2 is largely dispens-
able for bone development and Ezh2 inactivation does not ablate
cancer formation (J. Perry and S. Orkin, personal communica-
tion). Consequently, EZH2 does not serve an essential role in
all cancers but rather likely drives cancer formation via specific
activation.
Our results also provide mechanistic insight into the regulation
of EZH2 expression. The SWI/SNF complex is thought to regu-
late activation or repression of genes via alterations in nucleo-
some positioning. Our work shows that Snf5 binds directly to
the Ezh2 promoter and serves to prevent high-level expression.
That Snf5 is an important regulator of Ezh2 expression is also
supported by genome-wide ChIP-Chip analyses of Brg1 binding
in embryonic stem cells where it was found that Ezh2 is a target
of the SWI/SNF complex (Ho et al., 2009). Thus, our work estab-
lishes that Ezh2 is bound and regulated by Snf5, and required for
tumor formation after Snf5 loss. In addition to Ezh2, several other
PcG genes including Suz12, Eed, andBmi1 are bound by Brg1 in
embryonic stem cells, and these genes are also upregulated in
some primary human cancers lacking SNF5, although to a lesser
degree than EZH2. Therefore, SNF5 inactivation may lead to
overexpression of other PcG genes which also contribute to
oncogenesis. Indeed, while clear evidence linking SUZ12 and
EED to oncogenic transformation is still lacking, BMI1 has
been shown to possess clear oncogenic properties (Sparmann
and van Lohuizen 2006; Simon and Lange 2008). Collectively,
our work establishes that the regulatory relationship between
SWI/SNF and PcG complexes extends acrossmultiple cell types
and that perturbation of this relationship can contribute to
disease.October 19, 2010 ª2010 Elsevier Inc. 325
Figure 8. Model: Epigenetic Antagonism between EZH2 and SNF5
during Oncogenesis
(A) Antagonism of Polycomb target expression by SWI/SNF and PRC2. SNF5
also negatively regulates EZH2 function by modulating its expression.
(B) Perturbations in SWI/SNF activity lead to oncogenesis via imbalanced
PRC2 activity, aberrant epigenetic silencing of Polycomb targets and upregu-
lation of stem cell-associated programs.
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Antagonism between Polycomb and SWI/SNFHyperactivated Stem Cell-Associated Programs: A
Potential Mechanism Underlying Tumors that Arise
Following Snf5 Inactivation or Overexpression of PcG
Proteins
Stem cell-associated signatures have recently been found to be
enriched in tumors with more aggressive behavior and poorer
prognosis (Ben-Porath et al., 2008; Wong et al., 2008). While
these signatures are upregulated in many cancers and are an
important contributing factor during oncogenic transformation,
the mechanisms underlying specific activation of these
programs are not well understood. PcG proteins have a dynamic
role in safeguarding stem cell identity by maintaining the repres-326 Cancer Cell 18, 316–328, October 19, 2010 ª2010 Elsevier Inc.sion of lineage-specific genes, and hyperactive PcG function
may drive tumorigenesis through the repression of lineage-
specific genes and reversion to a more stem cell-like fate
associated with an increased capacity for self-renewal and
proliferation. The SWI/SNF complex has roles in lineage-specific
differentiation and perturbations in SWI/SNF activity block differ-
entiation, and thus may force cells to retain properties of a stem
cell. Furthermore, while PcG and SWI/SNF complexes have
opposing functions in the regulation of Hox gene expression in
Drosophila, it is not clear whether this antagonistic relationship
exists broadly during development or in the regulation of genetic
programs in stem cells. Our results show stem cell-associated
signatures are enriched in SNF5-deficient cancers and most
importantly that Snf5 inactivation leads to upregulation of stem
cell-associated programs in primary, untransformed cells. This
thus identifies SNF5 as a key regulator of these genetic
signatures. Conversely, PcG proteins regulate genetic programs
in stem cells and PcG overexpression has been shown to
promote increased proliferation and contribute to oncogenic
transformation. We show that reduction of Ezh2 levels in primary
cells leads to downregulation of stem cell-associated signatures,
demonstrating antagonistic effects of Snf5 and Ezh2 upon stem
cell-associated programs. Last, we show that activation of the
stem cell-associated signature caused by Snf5 loss is depen-
dent upon the presence of Ezh2. Collectively, our studies estab-
lish SNF5 as a regulator of stem cell-associated programs, show
opposing functions for SWI/SNF and Polycomb in the regulation
of these programs, and raise the possibility that imbalanced
regulation of stem cell-associated programsmay be a keymech-
anism leading to oncogenesis following overexpression of EZH2
or SNF5 inactivation.Targeted Therapy of EZH2
Our results may be therapeutically relevant to tumors caused by
inactivation of SNF5 by providing an in vivomodel cancer system
with which to test novel Ezh2 inhibitors, and may additionally be
applicable to the wide variety of cancers in which EZH2 is over-
expressed. Most cancers caused by SNF5 loss are aggressive
and respond poorly to current therapies. For example, despite
intensive therapy most children affected with atypical teratoid
rhabdoid tumor of the CNS, a highly malignant neoplasm driven
by inactivation of SNF5, die within a year of diagnosis (Chi et al.,
2009). Thus, more effective treatments are needed. Unlike
genetic mutations, which in the context of cancer are essentially
irreversible, epigenetic modifications are reversible and thus
represent attractive targets for intervention. Our results suggest
that targeted inactivation of EZH2, or alternatively blockade of
the epigenetic changes driven by EZH2, may be effective in
the treatment of patients bearing tumors driven by SNF5
inactivation.EXPERIMENTAL PROCEDURES
Snf5 and Ezh2 Inactivation and EZH2 Knockdown
Excision of Snf5 and Ezh2 in MEFs was carried out as previously described
(Isakoff et al., 2005; McKenna et al., 2008). EZH2 knockdown was achieved
using siRNAs and shRNAs targeting EZH2. For details regarding EZH2 knock-
down and cell culture experiments, see Supplemental Experimental
Procedures.
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The following antibodies were used: SNF5 (Bethyl, A301-087A), EZH2 (Cell
Signaling; 3147), Actin-HRP (Abcam; 20272-200), p16INK4a (Santa Cruz sc-
1207 and sc-468), p19ARF (Bethyl; A300-340A and Novus; NB200-106),
PARP1 (Cell signaling; 9542), and HRP-conjugated secondary antibodies
(Jackson Immunoresearch). For details, see Supplemental Experimental
Procedures.Murine Models
All mouse experiments adhere to guidelines at the Animal Resources Chil-
dren’s Hospital (ARCH) at the Children’s Hospital in Boston and have been
approved by the Institutional Animal Care and Use Committee (IACUC).
Chromatin Immuoprecipitation and ChIP-chip
A two-step crosslinking method was done for the Snf5 ChIP according to
Nowak et al. (2005) with some slight modifications. The Bethyl, A301-087A
Snf5 antibody, was used. p values were determined using a paired t test.
The H3K27me3 and Ezh2 ChIP experiments were performed similarly to the
above method using the H3K27me3 antibody (Upstate; 07-449) or the Ezh2
antibody (Millipore; 17-662) and a one-step crosslinking method where form-
aldehyde (1%) was added directly to the culture media and incubated for
10 min at 37C. p values were determined using an unpaired t test for the
H3K27me3 ChIP experiments in lymphoma and CD8+ T cell samples.
In MEFs, MAT scores for all densely tiled genes at a region 500 and +2500
of the TSS were calculated. Differences between H3K27me3 enrichment in
Snf5-deficient andWTMEFs were normally distributed (mean = 0.09). p values
were calculated as P(X > x) where X is the difference in MAT scores and x is the
difference for the indicated gene. For details, see Supplemental Experimental
Procedures.Gene Expression Data
Whole-genome expression analyses from Snf5-deficient lymphomas, Ezh2-
deficient MEFs, and Snf5 Ezh2-deficient MEFs were generated as previously
described (Isakoff et al., 2005). Expression data sets were analyzed using
the Gene Pattern data analysis software (Reich et al., 2006). GSEA was
performed as described previously (Subramanian et al., 2005). For details
regarding the generation and analysis of whole-genome expression data,
see Supplemental Experimental Procedures.ACCESSION NUMBERS
Whole-genome expression and ChIP-chip data are deposited in the GEO data
repository (accession number GSE23659).SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures, five figures, and
one table and can be found online at doi:10.1016/j.ccr.2010.09.006.ACKNOWLEDGMENTS
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